Reminder!
The tier level is assigned to the guideline, NOT to the specific search terms. For example, a Tier 1 guideline has at least one recommendation that meets criteria for Tier 1, but also could include tier 2 or 3 recommendations.
DO read the guidelines to find out about specific search terms.
DON’T rely on the overall tier classification of the guideline for the specified search terms.
See More FAQ
| Publication | Tier |
|---|---|
|
Next generation sequencing oncology panel, somatic or germline variant detection system (P170019)
The U.S. Food & Drug Administration Organization: The U.S. Food and Drug Administration (FDA) |
|
|
FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.
Kim G, et al. Clin Cancer Res. 2014 Oct 1;20(19):4994-5000. Organization: The U.S. Food and Drug Administration (FDA) |
|
|
NICE guidance on vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma.
Organization: The National Institute for Health and Care Excellence (NICE) |
|
|
BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.
Gonzalez D, et al. Br J Dermatol. 2013 Apr;168(4):700-7. doi: 10.1111/bjd.12248. Organization: Expert Panel |
|